Background: Polycystic ovary syndrome (PCOS) is associated with frequent overweight and abdominal obesity. Quantifying visceral adipose tissue (VAT) in PCOS patients can be a tool to assess metabolic risk and monitor effects of treatment. The latest dual-energy X-ray absorptiometry (DXA) technology can measure VAT and subcutaneous adipose tissue (SAT) in a clinical setting. Purpose: To compare DXA-measurements of VAT and SAT with the gold standard MRI in women with PCOS. Material and Methods: A cross-sectional study of 67 overweight women with PCOS was performed. Measurements of VAT and SAT were performed by DXA in a 5-cm thick transverse slice at the L4/L5 level and by MRI in a 1-cm thick transverse slice at the L3 level. Results: Mean (SD) DXA-VAT was 81 (34) cm 3 , DXA-SAT was 498 (118) cm 3 , MRI-VAT was 117 (48) cm 3 , and MRI-SAT was 408 (122) cm 3 . MRI and DXA measures of VAT (r ¼ 0.82, P < 0.001) and SAT (r ¼ 0.92, P < 0.001) correlated closely, and DXA-VAT was stronger correlated with MRI-VAT than BMI (r ¼ 0.62, P < 0.001) and waist circumference (r ¼ 0.60, P < 0.001). DXA-VAT coefficient of variance was 6.7% and inter correlation coefficient was 0.98. Bland-Altman analyses showed DXA to slightly underestimate VAT and SAT measurements compared with MRI. Conclusion: DXA and MRI measurements of VAT and SAT correlated closely despite different size of region of interest, and DXA-VAT was superior to waist circumference and BMI in estimating MRI-VAT. DXA showed high reproducibility making it is suitable for repeated measurements in the same individual over time.
Introduction
Waist circumference is part of the definition of the metabolic syndrome as it is a surrogate measurement for the amount of visceral adipose tissue (VAT). Studies in an unselected population have shown directly measured VAT to have an even stronger association with risk of type 2 diabetes (T2D), cardiovascular disease, and cancer than waist circumference and body mass index (BMI) (1) .
At present, VAT is measured by magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound (US). These methods are expensive, timeconsuming, or must be performed by specialists, which is why they are not part of routine screening programs for risk stratification in overweight patients. MRI and CT are considered gold standard for measuring VAT and have been tested against human cadavers (2) . Limitations in MRI are the small bore size, which excludes very obese or claustrophobic patients, and the presence of magnetic metal implants in the body, whereas CT exposes the patients to radiation. Software is now accessible for DXA scanners, making it possible to estimate VAT and subcutaneous adipose tissue (SAT) with an open scanner in an automated, cheap, and fast manner, only exposing the patients to minor radiation and producing directly interpretable results. However, it remains to be determined if the precision and quality of VAT and SAT, as measured by DXA, are sufficient to be used in a clinical setting.
Among women with polycystic ovary syndrome (PCOS) 50-80% are obese (3) and 50-70% are insulin-resistant (4), resulting in a fourfold increased risk of developing T2D (5) and 30% increased risk of cardiovascular disease (6) . Women with PCOS are known to have a higher waist circumference than BMI-matched controls and 50-60% have abdominal obesity (7) . Direct measures of VAT by CT or MRI show conflicting results when comparing the amount of VAT in PCOS and BMI-matched controls (8, 9) . PCOS, according to the Rotterdam criteria, contains four phenotypes depending on the combination of symptoms as the patients should just display at least two symptoms: oligo/amenorrhea; hyperandrogenism; and polycystic ovaries. The different phenotypes have slightly different metabolic profiles and thus most likely different risks of cardiovascular disease and type 2 diabetes (10). Measuring body composition and VAT in women with PCOS could be a tool to identify the women with a high risk of developing type 2 diabetes and cardiovascular disease in the heterogeneous PCOS population, as well as be a tool to monitor effects of treatment and lifestyle intervention.
In large-scale community-based studies, VAT has proven to be superior compared with BMI in predicting development of arteriosclerosis measured as carotid intima-media thickness in 2451 participants, particularly in women (11) , and in 3086 patients CT-VAT was associated with increased incidence of cardiovascular disease and cancer after five years of follow-up and adjustment for weight (12) . DXA has previously been validated against CT and recently against MRI (13, 14) , but to the best of our knowledge DXA VAT measurements have never been validated against gold standard in a PCOS cohort.
On these grounds, we aimed to investigate if DXA is suitable for quantification of VAT in a PCOS cohort by comparing DXA with MRI measurements of VAT and SAT and evaluating reproducibility.
Material and Methods
The design was a cross-sectional study on women with PCOS. The participants originated from baseline assessment of an intervention randomized clinical trial that evaluated the effect of the GLP-1 analogue liraglutide in PCOS as described in detail (15) . In short, inclusion criteria were: PCOS according to the Rotterdam criteria; BMI > 25; and/or insulin resistance as defined by fasting C-peptide > 600 pmol/L. Exclusion criteria were: history of diabetes or cardiovascular disease; hormonal contraceptives six weeks before randomization; and insulin sensitizers three months before randomization. DXA and MRI scans were performed on the same day after the participants produced a negative pregnancy test. Exclusion criteria for MRI were: claustrophobia; magnetic metal implants; or weight above 120 kg as the MRI bore had a diameter of approximately 50 cm. The study was approved by the Ethics Committee in Copenhagen, the Danish Medicines Agency (EudraCT 2013-003862-15), registered on www.clinicaltrial.gov (NCT02073929), and conducted according to the Helsinki Declaration. Informed consent was obtained from all participants.
DXA whole beam fan scan (Hologic Discovery, APEX 4.0, Bedford, MA, USA) measured the total abdominal adipose tissue (TAAT) in a 5-cm thick transverse section at a level corresponding to L4/L5. Based on scales of gray, the software identified the borders of the abdominal muscles and the investigator was able to adjust the lines if wanted. Measurement of subcutaneous fat between the skin and the outer abdominal wall on both flanks formed the basis of estimates of the amount of subcutaneous fat on the front and back of the abdomen, and thus the subcutaneous adipose tissue (SAT). VAT was calculated as TAAT minus SAT. Values for SAT were not part of the standard report and were obtained by accessing the program's data codes. To test the reproducibility, two consecutive DXA scans were performed on nine participants by the same operator only interrupted by the patient standing up and laying down again. During a whole beam fan scan with a scan time of 180 s, the patient received an approximate radiation dose of 0.01 mGy corresponding to 0.01 mSV.
The MRI scans were performed on an Achieva 3.0 T MRI system (Philips Medical Systems, Best, The Netherlands). A fast T1-weighted (T1W) turbo field echo (TFE) MRI sequence in a transverse plane was used for obtaining images for estimating adipose tissue volumes (TFE sequence, TFE factor ¼ 136, TR ¼ 10 ms, TE ¼ 2.3 ms, field of view ¼ 480 mm, respiratory trigger compensation with trigger delay of 1000 ms). Volumes of SAT and VAT were measured in a 1-cm thick slice at the L3 level using the ''segmentation tool'' in ''volume analysis'' at the Philips ViewForum work station. The L3 level was chosen, as studies report it to be the best predictor for total VAT (16, 17) , and single slice method because of the time factor as the scans were part of a larger study protocol (15) .
Waist circumference was measured in a standing position between the lower rib and the iliac crest; weighing was performed in light clothing on the same calibrated scale.
Statistical analysis was performed with SAS Enterprise Guide 7.1 (SAS Institute Inc., Cary, NC, USA). Bland-Altman plots with limits of agreement were applied to test the two methods against each other (18) . As the regions of interest (ROI) were different in size and anatomical position in the two methods, the mean ratios between the MRI volume and the DXA volume were calculated for VAT and SAT. Scaling factors were made from the mean ratios, and the DXA measurements were divided by the scaling factor for the Bland-Altman analysis according to the method described in another study with approximately the same anatomical ROIs (14) . Linear regression was used to determine the correlation with MRI as dependent variable and the standard error of the estimate (SEE) was calculated to describe the goodness-of-fit of the regression line (19) . One outlier was removed from the calculations after visual assessment and evaluation with Cook's distance. A P value of 0.05 was considered significant.
Results
Sixty-seven women with PCOS were examined by DXA and MRI. The participants had a mean (SD) age of 29.2 (6.2) years, weight of 92.0 (13.9) kg, BMI of 32.8 (4.6) kg/m 2 , and waist circumference of 101.5 (9.9) cm. Measurement of MRI-VAT resulted in a mean value of 117(48) cm 3 and DXA-VAT of 81 (34) cm 3 . Mean MRI-SAT was 408 (122) cm 3 and DXA-SAT was 498 (118) cm 3 . The MRI and DXA measurements for VAT (r ¼ 0.82, P < 0.01) and SAT (r ¼ 0.92, P < 0.01) were highly correlated ( Table 1 ). The correlation between MRI and DXA measures were stronger than the correlations between MRI and waist circumference or BMI ( Table 1) .
The mean ratios between MRI and DXA measurement for the Bland-Altman analyses were calculated and the following were used: DXA-VAT/3.76 and DXA-SAT/6.55. The mean (SD) difference between MRI-and DXA-VAT was 4 (25) cm 3 and the limits of agreement were [-45; 53] . Similarly, the mean difference between MRI-and DXA-SAT was 9 (45) cm 3 and limits of agreement were [-78 ; 97] (Fig. 1) .
The coefficient of variance (CV) for repeated DXA scans were 6.7% and 1.7% for VAT and SAT, respectively, and the intra class correlation coefficients (ICC) were 0.98 and 0.99, respectively.
Discussion
The present study showed a strong correlation between measurements of VAT and SAT by DXA as compared to the gold standard MRI in overweight women with PCOS. We found DXA-scans to be stronger correlated than waist circumference or BMI to MRI-VAT in a PCOS cohort. The Bland-Altman analyses were made between MRI and DXA-radios to compensate for the difference in size of ROI. DXA slightly underestimated both VAT and SAT. The precision of repeated DXA scans was sufficiently high to make this technology suitable for cardiovascular risk identification as well as for repeated measurements in PCOS.
Previously, VAT as measured by DXA has been tested predominately against CT, but also MRI, in cohorts of healthy people and found highly correlated. One study on 131 observations of DXA-VAT performed with a Hologic scanner found a correlation of r ¼ 0.93 with CT-VAT (20) and another study validated DXA-VAT measured with a Lunar scanner against CT on 124 healthy individuals and also found the measurements highly correlated (21) . Just recently, DXA-VAT was validated against MRI-VAT in the large the Dallas Heart Study with anatomical ROIs nearly identical to the ones used in the present study. Regarding the 1477 female participants, they found DXA and MRI measurements of VAT closely correlated with r 2 ¼ 0.82 (14) . Bredellea et al. (13) looked into different weight groups of otherwise healthy women (89 overweight, 27 normal weight, and 19 underweight participants) and compared DXA-VAT and DXA-SAT with CT measurements at the L4 level. They found DXA and CT highly correlated, but DXA overestimated VAT compared with CT, most pronounced in the underweight group, and suggested it could potentially be a methodological problem. Their results from Bland-Altman analyses do not agree with ours, but they looked at area (cm 2 ) of VAT and SAT at L4 instead of volume, making their results not directly comparable with ours (13) . The Dallas Heart cohort study, which used nearly the same MRI level and DXA volume measures as we did, found DXA to slightly underestimate VAT and SAT in line with our results (14) . This could indicate a methodological error, but could be compensated for by determining a normal range for DXA measurements of VAT and SAT. Reproducibility of DXA-VAT area (cm 3 ) have been tested in 101 healthy individuals by consecutive scans 14 days apart in a wide BMI range (range ¼ 18-52) and resulted in a technical error of measurement of 13.8 cm 3 and a standard error of a single determination of 8.1% (Hologic scanner, Apex 4.0) (22) .
Abdominal obesity in PCOS is influenced by androgens. In men, both supra-physiological and low endogenous androgen levels appear to facilitate VAT accumulation (23) . In women, both endogenous androgen excess, as seen in PCOS, and testosterone treatment in female-to-male gender transformation have been linked to increased abdominal obesity (23, 24) . Furthermore, increased VAT is associated with increased insulin resistance, although the secondary hyperinsulinemia worsens the symptoms of PCOS and increase the risk of developing type 2 diabetes (23) . This emphasizes the importance of quantifying VAT as part of the risk stratification of the individual PCOS patient.
In addition to the benefit of risk stratification, the DXA-VAT measurement has the potential to be a tool for monitoring the effects of medical and lifestyle interventions, which is of great importance in PCOS. Kuchenbecker et al. investigated 32 PCOS patients with anovulation who underwent six months of lifestyle intervention as part of fertility treatment (25) . Early and consistent loss of CT-measured VAT was associated with resumption of ovulation underlining the importance of monitoring the effect of treatment by direct measurements of VAT and not only weight.
A limitation to the study was that the MRI bore had a diameter excluding scans of participants weighing more than approximately 120 kg from MRI examination and thus validation of DXA scans in heavier individuals. The difference in size and anatomical placement of the ROIs are a bias in the interpretation of the results. Further, the choice to investigate overweight women with PCOS only, makes it difficult to extrapolate the results to the male population.
In conclusion, measurements of visceral and subcutaneous adipose tissue with DXA technology appear promising. DXA measures were highly correlated with MRI and DXA scans showed high reproducibility. DXA appeared to slightly underestimate both VAT and SAT compared with MRI measurement as seen in other studies. These results might be extended to different diseases and weight populations, and the DXA-scanner could earn a place in outpatient clinics as part of the assessment of patients' risk of developing type 2 diabetes and cardiovascular disease.
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